Expanding and stabilizing the current business and laying the groundwork for the next phase of growth
First written in FY2019. 10 of 18 entries say "Advanced", first in FY2024-Q2. Latest entry: 2026-10-13.
0 other companies' latest entry also says "Advanced".
- FY2026-H1AdvancedAnnual report
「Since the previous fiscal year, the company has pursued the development of its management foundation and upfront investment while targeting a transition to the phase of implementing its regenerative medicine-related business in society. The fiscal year ending October 2026 is positioned as a year in which these initiatives will be further advanced and the company will accelerate its structural transition to a problem-solving business model centered on cell and other processing technologies, while retaining the orthopedic field as its foundation.」
The initiatives aimed at implementing regenerative medicine-related business in society were given concrete form as a structural transition to a problem-solving business model centered on cell and other processing technologies and based on the orthopedic field, with the transition to be accelerated in the current fiscal year. - FY2025AdvancedAnnual report
「Having completed the selection and concentration of businesses under the heading “Optimizing the allocation of management resources,” the company will move into a phase of considering further streamlining in line with the scale of its businesses and the effective use of resources in new business areas.」
Regarding the policy of stabilizing the current business in parallel with pursuing future growth, the company indicated that it had completed the selection and concentration of businesses and would move into a phase of considering streamlining and reallocating resources to new business areas. - FY2025-H1ReframedAnnual report
「To date, the company has developed a regenerative medicine-related business for medical institutions, primarily in the orthopedic field, but going forward it will move into a phase of implementing regenerative medicine-related business in society together with medical institutions and partner companies.」
The company indicated a shift from expanding its business for medical institutions, centered on the orthopedic field, to a phase of implementing regenerative medicine in society together with medical institutions and partner companies. - FY2024-Q2AdvancedAnnual report
「The company will continue developing new services and actively promoting its existing businesses, while the completion of major personnel and capital investments is expected to lead to growth in profit alongside revenue growth.」
In addition to the policy of continuing to develop new services and promote existing businesses, the company specifically indicated that major personnel and capital investments had been completed and that profit was expected to grow alongside revenue. - FY2024-Q1RestatedAnnual report
「Selling, general and administrative expenses increased due to strategic cost investments, including workforce expansion, aimed at future business expansion and maximizing corporate value.」
The company continues to pursue a policy of investing in additional personnel and other areas in parallel with managing current performance and expanding the business and maximizing corporate value in the future. - FY2023-Q3RestatedAnnual report
「This resulted from advancing initiatives including office relocation and acquiring CPC to build the foundation for continued business expansion and further future growth, as well as hiring personnel, utilizing external contractors and conducting research and development.」
The company continues to pursue initiatives involving its offices, CPC, personnel, external contractors and research and development in parallel with current business expansion and future growth. - FY2023-Q1RestatedAnnual report
「This resulted from advancing initiatives including continuous business expansion, hiring personnel in anticipation of further future growth, utilizing external contractors and conducting research and development.」
The company continues to pursue initiatives involving personnel, external contractors and research and development in parallel with current business expansion and future growth. - FY2022RestatedAnnual report
「To pursue sustainable growth and enhance corporate value over the medium to long term, the company will maintain CSGR at a high level while appropriately advancing investments in human capital and in building its business foundation, as well as implementing diverse strategies, including creating new businesses that will change the future, collaborating with new partners and pursuing M&A.」
The company continues to pursue current growth in parallel with investments in human capital and its business foundation, as well as new businesses and partnerships. - FY2020RestatedAnnual report
「The company constantly formulates its next growth strategy and will spare no effort to lay the groundwork for the next phase of growth while expanding and stabilizing its current business.」
The policy of pursuing the expansion and stabilization of the current business in parallel with laying the groundwork for the next phase of growth continues. - FY2019First statedAnnual report
「The company constantly formulates its next growth strategy and will spare no effort to lay the groundwork for the next phase of growth while expanding and stabilizing its current business.」
The company has indicated a policy of pursuing the expansion and stabilization of its current business in parallel with future initiatives.